Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Receivables (2020 - 2026)

Neuroone Medical Technologies filings provide 7 years of Receivables readings, the most recent being $2.4 million for Q1 2026.

  • On a quarterly basis, Receivables rose 661.19% to $2.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.4 million, a 661.19% increase, with the full-year FY2025 number at $1.3 million, up 616.05% from a year prior.
  • Receivables hit $2.4 million in Q1 2026 for Neuroone Medical Technologies, down from $2.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.7 million in Q4 2025 to a low of $33237.0 in Q3 2022.
  • Median Receivables over the past 5 years was $410551.0 (2024), compared with a mean of $854323.1.
  • Biggest five-year swings in Receivables: plummeted 42.63% in 2025 and later surged 661.19% in 2026.
  • Neuroone Medical Technologies' Receivables stood at $95319.0 in 2022, then skyrocketed by 470.08% to $543399.0 in 2023, then surged by 335.94% to $2.4 million in 2024, then grew by 12.37% to $2.7 million in 2025, then fell by 8.84% to $2.4 million in 2026.
  • The last three reported values for Receivables were $2.4 million (Q1 2026), $2.7 million (Q4 2025), and $1.3 million (Q3 2025) per Business Quant data.